trastuzumab deruxtecan

Byondis, Medac File for European Approval of SYD985 for HER2-Positive Breast Cancer

EMA's CHMP Backs Approval for Enhertu, Lynparza for Two Breast Cancer Indications

Strata Oncology Enrolling Patients in Basket Trial Exploring Biomarker-Defined Indications

AstraZeneca Q1 Oncology Product Sales Increase 14 Percent Led by Tagrisso

Jury in Enhertu Patent Infringement Case Orders Daiichi Sankyo to Pay $41.8M in Damages

AstraZeneca, Daiichi Sankyo to Begin Regulatory Talks to Expand Enhertu Into HER2-Low Breast Cancer

AstraZeneca Q4 Oncology Revenues Grow 20 percent

In Brief This Week: AstraZeneca, Daiichi Sankyo, Orgenesis, Amgen

AstraZeneca, Daiichi Sankyo File for FDA Enhertu Approval in Second-Line HER2-Postive Breast Cancer

EMA to Review Daiichi Sankyo, AstraZeneca's Enhertu For Second-Line HER2-Positive Breast Cancer

Daiichi Sankyo, AstraZeneca Begin Phase III Trial of Enhertu in HER2-Mutant NSCLC

SABCS Clinicogenomic Study Sheds Light on HER2-Targeted Therapy Resistance

AstraZeneca, Daiichi Sankyo Unveil First Datopotamab Deruxtecan TNBC Data at SABCS

AstraZeneca's Q3 Oncology Revenues Grow 18 Percent

In Brief This Week: Daiichi Sankyo, AstraZeneca, Mary Bird Perkins Cancer Center, Guardant Health

Experts Consider Resistance, Combinations as Another HER2-Targeted Breast Cancer Drug Emerges

AstraZeneca, Daiichi Sankyo Begin New Gastric Cancer Enhertu Trial in China

AstraZeneca, Daiichi Sankyo Advance Regulatory Plans for Enhertu in Metastatic Breast Cancer